Reuters logo
BRIEF-Gritstone Oncology announces $92.7 mln series B preferred stock financing
September 7, 2017 / 10:43 AM / 2 months ago

BRIEF-Gritstone Oncology announces $92.7 mln series B preferred stock financing

Sept 7 (Reuters) - Gritstone Oncology:

* Announced successful completion of $92.7 million series B preferred stock financing

* Its targeting tumor-specific neoantigens is expected to enter clinical trials in mid-2018

* Proceeds from financing to be used to advance co’s tumor antigen identification platform & pipeline of cancer immunotherapies

* Financing round led by Lilly Asia Ventures, with participation from GV, Trinitas Capital (Beijing), Alexandria Venture Investments Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below